Prostate cancer (PCa) is one of the most common tumors of the male urogenital system, ranking the second among male malignancies worldwide. Age is a major risk factor for PCa, and population aging leads to an increasing incidence of the malignancy. Androgen-deprivation therapy (ADT) is currently the first-line treatment of PCa, but with the advance of the tumor, many of the patients become resistant to ADT and develop castration-resistant prostate cancer (CRPC), which marks a transition of PCa to a hormone-refractory state associated with a poor prognosis. Metastatic CRPC (mCRPC) is the terminal stage of the disease and a leading cause of death. Despite many new advances in the treatment of mCRPC, its prognosis remains poor. For patients with mCRPC, classical treatment options with chemotherapy and androgen-blocking agents have limited survival benefit, and radionuclide therapy has become a novel therapeutic option for mCRPC. This paper focuses on the development of the radionuclide therapy for mCRPC in recent years.
Keywords: radionuclides; castration-resistance; prostate cancer.